Synergistic inhibition of migration and invasion of breast cancer cells by dual docetaxel/quercetin-loaded nanoparticles via Akt/MMP-9 pathway

Int J Pharm. 2017 May 15;523(1):300-309. doi: 10.1016/j.ijpharm.2017.03.040. Epub 2017 Mar 21.

Abstract

Metastasis impedes the successful chemotherapy for breast cancer. In this study, an Akt inhibitor (quercetin, Qu) was co-delivered with a chemotherapeutic agent (docetaxel, DTX) by using hyaluronic acid (HA)-modified nanoparticles (NPs) as vectors to block metastasis. Dual DTX/Qu-loaded HA/polylactic-co-glycolic acid-polyethyleneimine NPs (PP-HA/NPs) were prepared through a modified emulsion solvent evaporation technique. The particle size of PP-HA/NPs with narrow polydispersity was 209.8±10.8nm. Wound healing assay revealed that Qu co-delivery and HA modification elicited synergistic inhibitory effects on cell motility. The downregulation of p-Akt and matrix metalloproteinase-9 (MMP-9) expression contributed to the significant inhibition of cell migration and invasion with inhibition rates of 95.6% and 99.3%, respectively. Further studies indicated that PP-HA/NPs could be efficiently uptaken by 4T1 breast cancer cells and could further induce cytotoxicity, decrease colony formation and promote cell apoptosis. Biodistribution assay demonstrated PP-HA/NPs also enhanced drug accumulation in the tumor and lungs and predicted that PP-HA/NPs could be employed as an effective therapy for primary tumor and pulmonary metastasis. Therefore, PP-HA/NPs could be a promising delivery system to treat metastatic breast cancer effectively.

Keywords: Akt/MMP-9 pathway; Breast cancer; Hyaluronic acid; Metastasis docetaxel; Quercetin.

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacokinetics
  • Antioxidants / administration & dosage*
  • Antioxidants / chemistry
  • Antioxidants / pharmacokinetics
  • Apoptosis / drug effects
  • Breast Neoplasms
  • Cell Line, Tumor
  • Cell Movement / drug effects
  • Cell Survival / drug effects
  • Docetaxel
  • Female
  • Hyaluronic Acid / administration & dosage
  • Hyaluronic Acid / chemistry
  • Hyaluronic Acid / pharmacokinetics
  • Imines / administration & dosage
  • Imines / chemistry
  • Imines / pharmacokinetics
  • Lactic Acid / administration & dosage
  • Lactic Acid / chemistry
  • Lactic Acid / pharmacokinetics
  • Matrix Metalloproteinase 9 / metabolism
  • Matrix Metalloproteinase Inhibitors / administration & dosage*
  • Matrix Metalloproteinase Inhibitors / chemistry
  • Matrix Metalloproteinase Inhibitors / pharmacokinetics
  • Mice, Inbred BALB C
  • Nanoparticles / administration & dosage*
  • Nanoparticles / chemistry
  • Polyethylenes / administration & dosage
  • Polyethylenes / chemistry
  • Polyethylenes / pharmacokinetics
  • Polyglycolic Acid / administration & dosage
  • Polyglycolic Acid / chemistry
  • Polyglycolic Acid / pharmacokinetics
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Proto-Oncogene Proteins c-akt / antagonists & inhibitors
  • Proto-Oncogene Proteins c-akt / metabolism
  • Quercetin / administration & dosage*
  • Quercetin / chemistry
  • Quercetin / pharmacokinetics
  • Taxoids / administration & dosage*
  • Taxoids / chemistry
  • Taxoids / pharmacokinetics
  • Wound Healing / drug effects

Substances

  • Antineoplastic Agents
  • Antioxidants
  • Imines
  • Matrix Metalloproteinase Inhibitors
  • Polyethylenes
  • Taxoids
  • poly(ethylene imine)
  • Docetaxel
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Polyglycolic Acid
  • Lactic Acid
  • Hyaluronic Acid
  • Quercetin
  • Proto-Oncogene Proteins c-akt
  • Matrix Metalloproteinase 9
  • Mmp9 protein, mouse